JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB277885

Human CREBBP knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CREBBP KO cell line available to order. KO validated by. Free of charge wild type control provided.

View Alternative Names

CBP_HUMAN, CREB-binding protein, Cyclic AMP responsive enhancer binding protein, KAT3A, RSTS, RTS, Rubinstein Taybi syndrome

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Disease

Carcinoma

Product details

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

Recommended control: Human wild-type A549 cell line (ab288558). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
CREBBP
Gene editing type
Knockout
Gene editing method
CRISPR technology
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CREBBP also known as CREB Binding Protein or CBP is a multifunctional protein with a molecular weight of approximately 265 kDa. This protein serves as a transcriptional coactivator and possesses intrinsic histone acetyltransferase (HAT) activity. CREBBP is ubiquitously expressed making it present in various tissues throughout the body. Its interaction with different transcription factors facilitates transcriptional activation by remodeling chromatin structure.
Biological function summary

CREBBP plays a pivotal role in regulating gene expression by serving as a coactivator that bridges transcription factors with the basal transcription machinery. CREBBP as part of large multiprotein complexes acetylates histones as well as non-histone proteins influencing chromatin accessibility and transcriptional efficiency. Its HAT activity contributes to the regulation of cell cycle differentiation and DNA repair.

Pathways

CREBBP integrates into both the p53 and Hedgehog signaling pathways modulating various cellular responses. In the p53 pathway CREBBP interacts with the tumor suppressor protein p53 enhancing p53’s ability to initiate expression of genes involved in cell cycle arrest and apoptosis. In the Hedgehog pathway CREBBP regulates transcription factors such as Gli proteins. The interplay between CREBBP and these pathways underlines its importance in maintaining cellular homeostasis and preventing oncogenesis.

Mutations or dysregulation of CREBBP are associated with Rubinstein-Taybi syndrome and various cancers including acute myeloid leukemia. In Rubinstein-Taybi syndrome CREBBP mutations impair cognitive development and skeletal malformations. In cancer particularly acute myeloid leukemia alterations in CREBBP disrupt normal cell growth regulation and lead to tumorigenesis. The protein's interaction with factors like p300 another histone acetyltransferase further emphasizes its critical involvement in these pathological conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com